WVE - Wave Life Sciences Ltd. EV/EBITDA Multiple
The development of Wave Life Sciences (WVE) is based on a strategic alliance with a global pharma behemoth, which determines the dynamics of the company's current EV/EBITDA ratio. Growth is supported by successes in treating Huntington's disease and GSK grants, as well as the precision of the PRISM platform in genome editing. The value of 0.00 serves as the final level mark, capturing the volatility of market valuations for this capital-intensive asset.
Comprehensive metric breakdowns and analytics for wavelifesciences.com (WVE)
- market price and analyst price targets:
- market capitalization statistics:
- issuer book value statistics:
- company liabilities and liquidity data:
Total Debt to Equity Ratio Wave Life Sciences|WVE - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Wave Life Sciences Ltd.|WVE - Company Total Debt Obligations|Debts to Book Capitalization Wave Pharma|WVE - Company Long-Term Liabilities|Company Short-Term Debts Wave Life Sciences|Quick Ratio wavelifesciences.com
- financial results and valuation multiples details:
WVE - Company Net Income|Expected Profit Wave Life Sciences|WVE - Price to Earnings Multiple|Forward P/E Multiple Wave Life Sciences|WVE - Price/Earnings to Growth Multiple|EV/EBITDA Multiple Wave Pharma|WVE - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Wave Life Sciences|WVE - Net earnings per share for the last four quarters|Year-over-year net earnings per share growth for the last 12 months wavelifesciences.com|WVE - Net earnings per share growth this year|Expected earnings per share growth for next year Wave Life Sciences
Comprehensive company analysis:Wave Life Sciences Corp WVE
Investors are assessing the resilience of Wave Life Sciences (WVE) through the ratio of the company's total enterprise value to its earnings before interest, taxes, depreciation, and amortization. By analyzing the EV/EBITDA multiple on the GURU.Markets platform, one can determine the fair value of assets, which for biopharmaceuticals depends not on GDP cycles, but on the availability of capital to fund long-term clinical trials of RNA-based drugs.
Competitors of Wave Life Sciences (WVE)
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization tempus.com TEM|Qiagen Corp - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Ionis Pharmaceuticals - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio repligen.com RGEN|RNA: EV/EBITDA Multiple|Company Value to Operating Income Before Depreciation Ratio CRSP (CRISPR Therapeutics Inc)|WGS (Sema4) - EV/EBITDA Multiple|Company Value to EBITDA Ultragenyx Corp RARE|Enterprise Value to EBITDA Ratio BEAM (Beam Therapeutics Inc.)|SRPT (sarepta.com) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Twist Bioscience, Inc. TWST|Total Company Value to Operating Income Before Depreciation Ratio 10x Genomics Inc (TXG)|Intellia - EV/EBITDA Multiple|Stoke Corp (STOK) - Enterprise Value to EBITDA Ratio|BLFS: EV/EBITDA Multiple|MAZE - Total Company Value to Operating Income Before Depreciation Ratio|SION (Sionna Therapeutics) - EV/EBITDA Multiple|Company Value to EBITDA Prime Medicine Inc PRME|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Taysha (TSHA)|uniQure Pharma - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple MGTX (MeiraGTx Holdings plc)|RGNX - Enterprise Value to EBITDA Ratio|Solid Biosciences - EV/EBITDA Multiple|Company Value to EBITDA Ocugen Inc|Pacific Biosciences of California (PACB) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|BNTC - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio DSGN|Enterprise Value to EBITDA Ratio rocketpharma.com (RCKT)|Enterprise Value to EBITDA Ratio FDMT (4D Molecular Therapeutics, Inc.)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization LXEO (lexeotx.com)|EV/EBITDA Multiple KRRO (Korro Bio)|Editas Corp (EDIT) - Company Value to EBITDA|Silence Therapeutics - EV/EBITDA Multiple|PRQR (ProQR Therapeutics N.V.) - Enterprise Value to Operating Income Before Depreciation|codexis.com (CDXS) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation SGMO|NAUT (Nautilus Biotechnology, Inc.) - EV/EBITDA Multiple|EV/EBITDA Multiple Metagenomi Therapeutics|Enterprise Value to EBITDA Ratio DTIL (Precision BioSciences)|Enterprise Value to EBITDA Ratio generationbio.com GBIO|EV/EBITDA Multiple BOLD (Boundless Bio)|EV/EBITDA Multiple Exicure Inc. XCUR|IMNN: Enterprise Value to EBITDA Ratio|PHIO: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|MBIO: EV/EBITDA Multiple|Company Value to EBITDA TransCode Therapeutics, Inc. (RNAZ)|Enterprise Value to EBITDA Ratio BNGO|APDN: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Bluebird Bio (BLUE)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization IPA (immunoprecise.com)|EV/EBITDA Multiple OMGA (Omega Therapeutics)|Total Company Value to Operating Income Before Depreciation Ratio singulargenomics.com (OMIC)|Regulus Therapeutics Inc. - EV/EBITDA Multiple|Company Value to Operating Income Before Depreciation Ratio SYRS|TBIO: EV/EBITDA Multiple|Company Value to EBITDA TRACON Pharmaceuticals, Inc (TCON)|Enterprise Value to EBITDA Ratio UBX
